Subcutaneous Implant

A subcutaneous implant is a solid or semi-solid depot placed in the subcutaneous tissue, usually of the inner upper arm, that releases drug continuously for months. Two architectures dominate. Reservoir implants surround a drug core with a rate-limiting polymer membrane, so flux is governed by the membrane and release approaches zero-order, changing little as the core depletes. Matrix implants disperse drug through a biodegradable lactide-glycolide polymer and release by diffusion and erosion together, usually giving a declining profile after an initial burst.

Peptide examples are established in endocrinology. The histrelin implant is a non-biodegradable reservoir rod delivering a GnRH agonist continuously for about a year, then removed and replaced. Goserelin is a biodegradable lactide-glycolide cylinder introduced through a wide-bore needle and needing no removal. Both exploit the same pharmacology: continuous, non-pulsatile GnRH receptor stimulation desensitises the axis, the opposite of what pulsatile delivery of the same peptide achieves.

An implant changes what can be concluded about exposure. Adherence stops being a variable, peak-to-trough swings largely disappear, and a compound with a short intrinsic half-life behaves as though it had a long one because absorption rather than elimination becomes rate-limiting. The price is reversibility, since a depot cannot be withdrawn except surgically.

The misreading to watch for is treating a stated duration as a promise of constant plasma concentration. Matrix implants in particular decline over their life, and the tail can fall below the concentration that produced the effect. Separately, the hormone pellets marketed by wellness clinics are compounded products whose release characteristics were never established as an approved implant's are.